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Edited by Laszlo NagyAbstract Advanced glycation end product (AGE)-their receptor
(RAGE) and angiotensin II (AII) are implicated in diabetic ret-
inopathy. However, a crosstalk between the two is not fully
understood. In vivo, AGE injection stimulated RAGE expression
in the eye of spontaneously hypertensive rats, which was blocked
by an AII-type 1 receptor blocker, telmisartan. In vitro, AII-type
1 receptor-mediated reactive oxygen species generation elicited
RAGE gene expression in pericytes through NF-jB activation.
Further, AII augmented AGE-induced pericyte apoptosis, the
earliest hallmark of diabetic retinopathy. Our present study
may implicate a crosstalk between AGE-RAGE system and
AII in diabetic retinopathy.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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for AGEs1. Introduction
There is a growing body of evidence that hypertension is an
independent risk factor for the incidence and progression of
diabetic retinopathy and that strict blood pressure (BP) con-
trol achieves a clinically important reduction in the risk of pro-
gression of diabetic retinopathy [1–4]. Furthermore, recent
clinical studies suggest active participation of the renin–
angiotensin system (RAS) in the pathogenesis of diabetic
retinopathy [5,6]. Indeed, interruption of the RAS with angio-
tensin-coverting enzyme inhibitors or angiotensin II (AII)-type
1 receptor blockers (ARBs) has been reported to reduce renal
or retinal disease progression in diabetic patients with hyper-
tension [7–9].
Non-enzymatic modiﬁcation of proteins by reducing sugars,
a process that is also known as Maillard reaction, progress atAbbreviations: RAS, renin–angiotensin system; AII, angiotensin II;
ARBs, AII-type 1 receptor blockers; AGEs, advanced glycation end
products; RAGE, receptor for AGEs; SHR, spontaneously hyperten-
sive rats; DPI, diphenylene iodonium; NAC, N-acetylcysteine; BSA,
bovine serum albumin; ROS, reactive oxygen species; RT-PCR, reve-
rse transcription-polymerase chain reaction; BP, blood pressure
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doi:10.1016/j.febslet.2005.06.058an extremely accelerated rate under diabetes, leading to the
formation of advanced glycation end products (AGEs)
in vivo [10,11]. Recent understandings of this process have re-
vealed that the AGE-their receptor (RAGE) system plays a
central role in the pathogenesis of diabetic vascular complica-
tion as well [12–15]. Engagement of RAGE by AGEs activates
its downstream signaling and subsequently evokes oxidative
stress and inﬂammatory responses in vascular wall cells, thus,
contributing to the development and progression of diabetic
retinopathy [16–19]. However, the crosstalk between the
AGE-RAGE system and the RAS in diabetic retinopathy is
not fully understood. In this study, we ﬁrst investigated
whether AII-type 1 receptor interaction was involved in
RAGE expression in the eye of spontaneously hypertensive
rats (SHR). Then we examined whether AII upregulated
RAGE mRNA levels in cultured retinal pericytes in vitro
and the way that it might achieve this eﬀect. We further studied
here whether AII could augment the cytopathic eﬀects of
AGEs on pericytes through RAGE overexpression.2. Materials and methods
2.1. Materials
AII, diphenylene iodonium (DPI), an inhibitor of NADPH oxidase
and N-acetylcysteine (NAC) were purchased from Sigma (St. Louis,
MO, USA). Telmisartan, an ARB, was generously gifted from Boeh-
ringer Ingelheim (Ingelheim, Germany). GeneAmp RNA PCR Core
Kit was from Applied Biosystems (Branchburg, NJ, USA).
2.2. Preparation of AGE-proteins
AGE-bovine serum albumin (BSA) was prepared as described previ-
ously [20]. Brieﬂy, BSA was incubated under sterile conditions with D-
glyceraldehyde for 7 days. Then unincorporated sugars were removed
by dialysis against phosphate-buﬀered saline. Control non-glycated
BSA was incubated in the same conditions except for the absence of
reducing sugars. Preparations were tested for endotoxin using Endosp-
ecy ES-20S system (Seikagaku Co., Tokyo, Japan); no endotoxin was
detectable. The extent of chemical modiﬁcation was determined with
2,4,6-trinitrobenzenesulfonic acid and reported as the diﬀerence be-
tween lysine residues of modiﬁed and unmodiﬁed protein preparations
[20]. The extent of lysine modiﬁcation (%) of modiﬁed BSA prepara-
tions was 65% for AGE-BSA.
2.3. Animal study
Seven-week-old normoglycemic SHR (Charles River Breeding Lab-
oratories, Yokohama, Japan) were used in this study. After a 1-week
adaptation period, rats were given tail vein injections with 2 mgblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀects of oral administration of telmisartan on RAGE
expression in the eye of SHR. SHR were given tail vein injections
with 2 mg AGE-BSA (n = 4) or non-glycated BSA (n = 4) or with 2 mg
AGE-BSA followed by oral administration of telmisartan (2 mg/kg/
day) (n = 4) every day for up to 10 days. Then, RAGE expression in
the eye was analyzed by Western blots. Similar results were obtained in
three independent experiments.
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BSA followed by oral administration of telmisartan (2 mg/kg/day)
(n = 4) every day for up to 10 days. Then, the rats were sacriﬁced
1–2 h after injection on the ﬁnal day. This AGE administration signif-
icantly (P < 0.01) increases serum AGE levels, but telmisartan treat-
ment did not aﬀect the AGE levels; the serum AGE levels of
non-glycated BSA-treated, AGE-BSA-treated, and AGE-BSA plus tel-
misartan-treated SHR were 21.7 ± 0.3, 26.0 ± 0.3, and 25.3 ± 0.3 lg/
ml, respectively. All animal procedures were conducted according to
the guidelines provided by the Kurume University Institutional Ani-
mal Care and Use Committee under an approved protocol.
2.4. Western blotting analysis
Proteins were extracted from enucleated eyes, and then separated by
SDS–polyacrylamide gel electrophoresis and transferred to nitrocellu-
lose membranes (Biorad, Hercules, CA, USA) as described previously
[21]. Membranes were probed with 1:1000 dilution of anti-serum
against RAGE [22] or 1:5000 dilution of monoclonal antibody against
a-tubulin (Sigma), and then the immune complexes were visualized
with an enhanced chemiluminescence detection system (ECL; Amer-
sham Bioscience, Buckinghamshire, United Kingdom).
2.5. Cells
Pericytes were isolated from bovine retina and maintained in Dul-
beccos modiﬁed Eagles medium containing 5.5 mM glucose (Sigma)
supplemented with 20% of fetal bovine serum (ICN Biomedicals Inc.,
Aurora, OH,USA) as described previously [23]. AGE or AII treatments
were carried out in a medium containing 2% fetal bovine serum.
2.6. Measurement of intracellular ROS generation
Pericytes were incubated with or without 100 nM AII in the presence
or absence of 100 nM telmisartan or 50 nM DPI for the indicated time
periods. Then the intracellular formation of reactive oxygen species
(ROS) was measured using the ﬂuorescent probe CM–H2DCFDA
(Molecular Probes, Eugene, OR, USA) [24].
2.7. Measurement of luciferase activity
Plasmid, containing the NF-jB promoter attached upstream to the
luciferase reporter gene, was kindly provided by Dr. T. Fujita, Depart-
ment of Tumor Cell Biology, Tokyo Metropolitan Institute of Medical
Science. Luciferase activity was measured as described previously [25].
2.8. Primers and probes
Sequences of the upstream and downstream primers used in the
semi-quantitative reverse transcription-polymerase chain reaction
(RT-PCR) were 5 0-ATGGAAACTGAACACAGGCC-3 0 and 5 0-
CACACATGTCCCCACCTTAT-3 0 for detecting bovine RAGE
mRNA [26]. Sequences of the primers for human b-actin mRNAs were
the same as described previously [20].
2.9. Semi-quantitative RT-PCR
Poly(A)+RNAs were isolated from pericytes treated with or without
100 nM AII in the presence or absence of 100 nM telmisartan or 1 mM
NAC for 4 h, and then analyzed by RT-PCR as described previously
[20]. The amounts of poly(A)+RNA templates (30 ng) and cycle num-
bers (37 cycles for RAGE gene and 22 cycles for b-actin gene) for
ampliﬁcation were chosen in quantitative ranges, where reactions pro-
ceeded linearly, which had been determined by plotting signal intensi-
ties as functions of the template amounts and cycle numbers [26].
2.10. Measurement of growth of pericytes
Pericytes were preincubated in the presence or absence of 100 nM
AII for 4 h. After washing with phosphate-buﬀered saline once, the
cells were treated with various concentrations of AGE-BSA or
100 lg/ml non-glycated BSA for 2 days, and then the number of viable
cells was determined as described previously [27].
2.11. Measurement of apoptotic cell death in pericytes
Pericytes were preincubated in the presence or absence of 100 nMAII
for 4 h. After washing with phosphate-buﬀered saline once, the cells
were treated with various concentrations of AGE-BSA or 100 lg/ml
non-glycated BSA for 2 days. Then the cells were lysed and thesupernatant analyzed in an enzyme-linked immunosorbent assay for
DNA fragments (Cell Death Detection enzyme-linked immunosorbent
assay, Roche Molecular Biochemicals, Mannheim, Germany) accord-
ing to the manufacturers instructions. The amount of apoptosis is
shown as the relative absorbance value of the control cells [28].
2.12. Statistical analysis
All values were presented as means ± S.E. Unless otherwise indi-
cated, one-way ANOVA followed by the Scheﬀe F test was performed.
For statistical comparisons of the values between no treatment and AII
pretreatment (Fig. 5), unpaired t test was performed; P < 0.05 was con-
sidered signiﬁcant.3. Results
3.1. Eﬀects of telmisartan on RAGE expression in the eye of
SHR
We ﬁrst investigated whether AII-type 1 receptor interaction
was involved in RAGE expression in the eye of SHR. For this,
we examined eﬀects of an ARB, telmisartan on RAGE expres-
sion in the eye of AGE-injected SHR. As shown in Fig. 1, tel-
misartan blocked the AGE-induced RAGE expression in the
eye, decreasing its level below that of non-glycated BSA-in-
jected SHR. Telmisartan treatment for 10 days signiﬁcantly de-
creased BP level; systolic BP in non-glycated BSA-treated,
AGE-BSA-treated, and AGE-BSA plus telmisartan-treated
SHR were 194.8 ± 3.7, 195.0 ± 3.6, and 182.8 ± 1.5 mmHg,
respectively. The serum creatinine levels of non-glycated
BSA-treated, AGE-BSA-treated, and AGE-BSA plus telmisar-
tan-treated rats were 0.33 ± 0.02, 0.33 ± 0.02, and 0.35 ±
0.03 mg/dl, respectively.
3.2. Eﬀects of AII on ROS generation in pericytes
We next investigated eﬀects of AII on ROS generation in
cultured pericytes. As shown in Fig. 2A, 100 nM AII signiﬁ-
cantly increased ROS generation in pericytes; 2- or 4-h incuba-
tion of 100 nM AII increased intracellular ROS generation by
about 1.5-fold. Telmisartan or DPI, an inhibitor of NADPH
oxidase was found to completely inhibit the AII-induced in-
crease in ROS generation, thus, suggesting that AII-type 1
receptor interaction elicited ROS generation in cultured peri-
cytes via NADPH oxidase activity (Fig. 1B). Although high
glucose elicited the mitochondrial ROS generation in pericytes
[29], we used here Dulbeccos modiﬁed Eagles medium
containing 5.5 mM glucose. Furthermore, there is a growing
Fig. 2. Eﬀects of AII on ROS generation in pericytes. (A, B) Pericytes
were treated with or without 100 nM AII in the presence or absence of
100 nM telmisartan or 50 nM DPI for the indicated time periods, and
then ROS were quantitatively analyzed. The percentage of ROS
generation is indicated on the ordinate and related to the value for the
control with no additives. (A) *P < 0.05 and **P < 0.01 compared to
the value of the control without AII. (B) *P < 0.05 and **P < 0.01
compared to the value with AII alone.
Fig. 3. Eﬀects of AII on NF-jB activity in pericytes. Pericytes were
treated with or without 100 nM AII in the presence or absence of
100 nM telmisartan or 1 mM NAC for 4 h, and then NF-jB luciferase
activity was measured. The percentage of luciferase activity is related
to the value of the control. *P < 0.05 and **P < 0.01 compared to the
value with AII alone.
Fig. 4. Eﬀects of AII on RAGE gene expression in pericytes. Pericytes
were treated with or without 100 nM AII in the presence or absence of
100 nM telmisartan or 1 mM NAC for 4 h, and then analyzed by RT-
PCR. Lower panels show the quantitative representation of RAGE
gene induction. Data were normalized by the intensity of b-actin
mRNA-derived signals and related to the value of the control.
*P < 0.05 compared to the value with AII alone.
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NADPH oxidase activity [30]. These are reasons why DPI
completely ameliorated ROS production.
3.3. Eﬀects of AII on NF-jB promoter activity in pericytes
ROS modulate a number of gene expressions through the
activation of transcriptional factor NF-jB [31]. Therefore,
we examined whether AII could induce transcriptional activa-
tion of NF-jB in pericytes. As shown in Fig. 3, AII signiﬁ-
cantly increased the NF-jB promoter activity. Telmisartan
as well as an anti-oxidant NAC was found to completely block
the AII-induced increase in NF-jB promoter activity. Telmi-
sartan or NAC alone did not aﬀect NF-jB promoter activity
(data not shown). We used here low glucose-containing
Dulbeccos modiﬁed Eagles medium. This is a reason why tel-
misartan did not aﬀect the basal NF-jB activity in pericytes.3.4. Eﬀects of AII on RAGE mRNA levels in pericytes
The promoter of RAGE gene was shown to contain diﬀerent
recognition sites for transcription factors NF-jB, which activ-
ity was associated with RAGE overexpression in vascular cells
[32,33]. So, we next studied whether AII could aﬀect gene
expression of RAGE in pericytes. As shown in Fig. 4, AII
signiﬁcantly upregulated RAGE mRNA levels, which were
4268 S. Yamagishi et al. / FEBS Letters 579 (2005) 4265–4270completely inhibited by telmisartan or NAC. Telmisartan or
NAC alone did not aﬀect RAGE mRNA levels in pericytes
(data not shown).
3.5. Eﬀects of AII pretreatment on AGE toxicity to pericytes
It is probable that the increased RAGE proteins could fur-
ther transduce the AGE signals, thus, leading to exacerbation
of AGE actions on pericytes. Therefore, we next investigated
eﬀects of AII pretreatment on growth and apoptosis of peri-
cytes. As shown in Fig. 5A and B, pretreatment of AII signif-
icantly augmented growth inhibitory as well as pro-apoptotic
eﬀects of AGEs on pericytes.Fig. 5. Eﬀects of AII pretreatment on viable cell number and
apoptosis of AGE-exposed pericytes. Pericytes were preincubated in
the presence or absence of 100 nM AII for 4 h. After washing with
phosphate-buﬀered saline once, the cells were treated with various
concentrations of AGE-BSA or 100 lg/ml non-glycated BSA for 2
days. Then the viable cell number (A) and apoptotic cell death (B) of
pericytes were measured. +P < 0.05 and ++P < 0.01 compared to the
value of non-treated cells with non-glycated BSA. *P < 0.05 and
**P < 0.01 compared to the value of AII-pretreated cells with non-
glycated BSA.4. Discussion
In the present study, we demonstrated for the ﬁrst time that
telmisartan, a commercially available ARB, blocked RAGE
overexpression in the eye of AGE-treated SHR. Furthermore,
we found here that AII-type 1 receptor interaction-mediated
ROS generation stimulated RAGE gene induction via NF-
jB activation, thereby augmenting the cytopathic eﬀects of
AGEs to cultured retinal pericytes. These observations suggest
that there could exist a functional crosstalk between the AGE-
RAGE system and the AII-type 1 receptor in the pathogenesis
of diabetic retinopathy.
In this study, we chose SHR to examine the involvement of
AII-type 1 receptor system in tissue expression of RAGE, be-
cause these rats display an enhanced local RAS, including the
eye [34–36]. When SHR were injected intravenously with 2 mg
AGE-BSA for 10 days, which increases serum AGE levels to
those of diabetic situation (unpublished data), RAGE expres-
sion in the eye was increased by about 2-fold (Fig. 1). Telmi-
sartan blocked the AGE-induced RAGE overexpression,
thus, decreasing its level below that of non-glycated BSA-in-
jected SHR. These results suggest that both basal and AGE-
elicited RAGE expression in the eye were under the control
of the AII-type 1 receptor system. In the study, telmisartan
treatment did not aﬀect the circulating AGE levels or renal
function. Therefore, it is unlikely that telmisartan treatment
decreases RAGE expression via a reduction in one of its
ligands, AGEs.
In order to elucidate the molecular mechanism for RAGE
upregulation by AII, we did in vitro retinal pericyte experi-
ments, because the above in vivo data cannot completely ex-
clude the possibility that BP lowering eﬀects of telmisartan
could contribute to RAGE suppression in the eye. In this
study, AII signiﬁcantly increased ROS generation in cultured
retinal pericytes, which was blocked by telmisartan or an
inhibitor of NADPH oxidase, DPI. Further, telmisartan or
an anti-oxidant NAC completely prevented the AII-induced
NF-jB activation and subsequent upregulation of RAGE
mRNA levels in pericytes. Taken together, these results sug-
gest that blockade by telmisartan of the AII-type 1 receptor
system inhibited RAGE induction in pericytes by suppressing
NADPH oxidase-mediated ROS generation and NF-jB acti-
vation. In support of this speculation, redox-sensitive NF-jB
promoter activity is reported to be required for the induction
of the RAGE gene expression in vascular cells, including peri-
cytes [32,33]. Lander et al. have reported recently that AGE-
RAGE-mediated induction of cellular oxidant stress triggers
a cascade of intracellular signals involving Ras and mitogen-
activated protein kinase, culminating in NF-jB activation in
smooth muscle cells, macrovascular counterparts of pericytes
[23,37]. This pathway could provide a vicious cycle of damage
in diabetic retinopathy.
We also demonstrated here for the ﬁrst time that AII pre-
treatment potentiated the AGE-induced growth retardation
as well as apoptotic cell death of pericytes (Fig. 5). Retinal
pericytes play an important role in the maintenance of micro-
vascular homeostasis [23,38]. It has been postulated that many
of characteristic changes of diabetic retinopathy are the conse-
quent of the loss of pericytes [23,24,39]. Further, the RAS in
the eye is activated in diabetes or hypertension [40,41] and that
RAGE mediates the AGE-induced cytotoxicity to retinal
pericytes [19,26]. These observations suggest that the RAGE
S. Yamagishi et al. / FEBS Letters 579 (2005) 4265–4270 4269induction by AII could play an important role in accelerated
apoptosis of pericytes in diabetic patients with hypertension,
thereby providing a molecular basis for understanding why
the association of diabetes with hypertension increases the risk
of diabetic retinopathy [1–4]. Our present study indicates that
blockade by telmisartan of the crosstalk between the AGE-
RAGE system and the RAS may be a promising target for
therapeutic intervention in diabetic retinopathy with hyperten-
sive patients.
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